glp 1 resistance GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Do Fasting GLP-1 and GIP

What are the side effects of anifrolumab-fnia

Results were published in the New England Journal of Medicine in September 2025

A 2023 pharmaceutical review cautioned that BPC-157 increases VEGFR2 expression and that VEGF pathways are active in many human cancers

J Pharmacopunct 25(2):79 Cui J, Jia J (2021) Natural COX-2 inhibitors as promising anti-inflammatory agents: an update

Karen Mann, MD , Nooms Medical Director, to help explain what this so-called GLP-1 supplement can and cant doand how its different from medications like Wegovy and Zepbound

The first of these gains (022,242,355) with loss of heterozygosity (LOH) included the entire TP53 gene (7,565,0977,590,856), while the second region of gain (25,295,03230,784,881) included the entire NF1 (25,295,03281,195,210), EZH1 (40,852,29340,897,071) and SUZ12 (25,295,03281,195,210) genes (Supplementary Table 1)